| 引用本文: | 荣春玲,孟倩颖,胡阳敏,何萍,戴海斌.人血白蛋白在烧伤休克复苏中的有效性和安全性研究[J].中国现代应用药学,2020,37(23):2902-2906. |
| RONG Chunling,MENG Qianying,HU Yangmin,HE Ping,DAI Haibin.Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(23):2902-2906. |
|
| 本文已被：浏览 5249次 下载 2635次 |
码上扫一扫！ |
|
|
| 人血白蛋白在烧伤休克复苏中的有效性和安全性研究 |
|
荣春玲1,2, 孟倩颖1,3, 胡阳敏1, 何萍1, 戴海斌1
|
|
1.浙江大学医学院附属第二医院, 杭州 310009;2.杭州市江干区人民医院, 杭州 310016;3.南京军区福州总医院四七六医院, 福州 350002
|
|
| 摘要: |
| 目的 考察白蛋白在烧伤休克复苏中的有效性和安全性，为白蛋白的合理使用提供理论基础。方法 采用回顾性病例对照研究的方法，收集浙江大学医学院附属第二医院2011年1月—2018年12月烧伤科住院患者中需要进行抗休克液体复苏的患者信息，根据烧伤的严重程度分为中重度烧伤组（20%<烧伤面积≤50%）、特重烧伤组（烧伤面积>50%），根据是否使用白蛋白复苏分为白蛋白组、非白蛋白组。主要结局指标为死亡率，次要结局指标为住院天数、呼吸机使用情况、复苏液体使用情况和并发症发生情况。结果 20%<烧伤面积≤50%的患者和烧伤面积>50%的2组患者白蛋白组与非白蛋白组的死亡率、住院天数、呼吸机使用例数、液体使用情况及并发症发生情况均无统计学差异；白蛋白组患者的机械通气天数高于非白蛋白组（P=0.003），但多因素方差分析结果显示，这与白蛋白的使用无关；在患者住院期间，没有发现由于人血白蛋白的使用而引发的明显不良反应。结论 在烧伤休克患者液体复苏的过程中，人血白蛋白的使用对治疗结局的改善不明显，但也没有发生明显的不良反应。 |
| 关键词: 烧伤 休克 复苏 人血白蛋白 疗效 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.23.016 |
| 分类号:R969.4 |
| 基金项目:浙江省药学会医院药学专项科研资助项目（2013ZYY28） |
|
| Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery |
|
RONG Chunling1,2, MENG Qianying1,3, HU Yangmin1, HE Ping1, DAI Haibin1
|
|
1.Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China;2.The People's Hospital of Hangzhou Jianggan District, Hangzhou 310016, China;3.No. 476 Hospital of Fuzhou General Hospital of Nanjing Military Area, Fuzhou 350002, China
|
| Abstract: |
| OBJECTIVE To explore the effects and safety of human albumin in burn shock recovery, and to provide a theoretical basis for its rational use. METHODS The retrospective case-control study was conducted. Patients who admitted to the burn ward and needed fluid resuscitation during the period of January 2011 to December 2018 in Second Affiliated Hospital, Zhejiang University School of Medicine were identified. Patients were divided into two groups according to the severity of burns, the patients with a 20%50% constituted the severest burn group, and albumin resuscitation was divided into albumin group and non-albumin group. The primary outcome was mortality, and the secondary outcomes included hospital stay, ventilator supporting, fluid use, and complications. RESULTS In the patients with 20%50%, there were no significant differences in mortality, hospital stay, ventilator supporting, fluid use, and complications between the albumin group and the non-albumin group; the number of ventilator days in the albumin group was higher than that in the non-albumin group(P=0.003), but the multivariate analysis of variance showed that it had no association with the albumin use. During the patient's hospitalization, there was no significant adverse effects caused by the use of human albumin. CONCLUSION In the patients with burn shock resuscitation, the use of human albumin don't improve the clinical outcomes, and there is no obvious adverse reactions occurred. |
| Key words: burns shock recovery human albumin effect |
